Fish Oil Composition of Omacor and the GISSI Trial

American Journal of Cardiology

Volumn 99, Issue 10, 2007, Pages 1483-1484

  Bays, Harold ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; SUDDEN DEATH;

CARDIOVASCULAR DISEASES; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 34247556014     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.01.012     Document Type: Letter

References (6)

1. Ito M.K., Marrs J., and Williams C. Omacor effects on serum lipids and clinical outcome. Am J Cardiol 99 (2007) 145
2. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 98 suppl (2006) 71i-76i
3. Gruppo Italiano per lo Studio Della Sopravvivenza nell'Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and Vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
4. Erratum. Lancet 357 (2001) 642
5. Reliant Pharmaceuticals, Inc. Clinical Trial Data. Available at: http://www.omacor.com/ ?module=articles;action=articleFolder.public OpenFolder;ID=227. Accessed January 9, 2007.
6. Reliant Pharmaceuticals, Inc. Summary of product characteristics. Available at: http:// www.omacor.com/filestore/OmacorSPC.pdf. Accessed January 9, 2007.